ClinicalTrials.gg
RecruitingNCT07309172Updated Dec 30, 2025

KetoBrain: Brain Energy Metabolism in Schizophrenia

An observational study in Schizophrenia Disorder, sponsored by Ole Köhler-Forsberg. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Ole Köhler-Forsberg · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
34
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Schizophrenia with a site in Denmark — 10 open to participants now, 12 under way, none of them phase 3. Schizophrenia · Denmark.

Planned enrollment
10th of 11
34 · median 203
Started
2025
with 4 others
Observational
12 of 79
4 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
77th of 79
by date

Among the 79 studies in Schizophrenia with a site in Denmark, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2025, is one of 12 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 77th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

10 of the 79 studies in Schizophrenia with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Schizophrenia with a site in Denmark, or all of them as a file.
02

Study summary

Objective The objective is to recruit antipsychotic-naïve patients at the first diagnosis with a first-episode schizophrenia disorder (FES) to study ketone metabolism of the brain via PET neuroimaging. Participants will undergo PET neuroimaging at baseline before start of antipsychotic treatment and after 4-8 weeks of antipsychotic treatment including an additional clinical follow-up visit after 6 months. In addition, a healthy control group with one baseline visit will be recruited.

Study design Non-interventional neuroimaging study with pre-defined follow-up visits.

Patients Patients with a FES (ICD-10: F20) aged 18-35 years who are antipsychotic-naïve including age- and sex-matched healthy controls.

Sample size This is an observational pilot project. Currently, no studies have measured brain ketone metabolism before and after AP intake. Assuming a 50% dropout rate at follow-up, the investigators aim to recruit 22 patients to obtain 12 full datasets - a sample size commonly used in PET studies. Healthy controls will only have one study day, so no dropouts are expected - aiming at a sample size of 12 healthy controls.

Procedures Patients will be included at the first FES diagnosis. Before inclusion, an interview with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview will validate the diagnosis. At baseline and follow-up (details in the full protocol and Table 1), patients will be rated by use of the 6-item Positive and Negative Syndrome Scale (PANSS-6), the Clinical Global Impression Severity Scale (CGI-S), the Global Assessment of Functioning Scale (GAF), Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT), Fagerström Test for Nicotine Dependence (FTND), and the Calgary Depression Scale for Schizophrenia (CDSS). The Matrics Consensus Cognitive Battery (MCCB), which consists of 10 cognitive tests, will measure cognition. Heart rate, blood pressure, height, body weight, waist and hip circumference will be recorded. Patients will be treated according to clinical indication, i.e., they will receive routine clinical care at the local psychiatric hospital and participation in this study will not affect the treatment.

Follow-up Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation. A re-scan will be performed after 4-8 weeks of antipsychotic treatment.

Endpoints The primary endpoints are

  1. Brain ketone and glucose metabolism in FES before antipsychotic treatment compared to healthy controls measured via PET
  2. Brain ketone and glucose metabolism in FES after antipsychotic treatment

Risks and Safety Patients will follow treatment-as-usual at their local psychiatric hospital, with the clinicians from the local hospital being responsible for safety monitoring according to local treatment guidelines. Participation in the present study will not delay clinically indicated antipsychotic treatment. Blood sample results will be obtained from the patient's medical record (MidtEPJ) at the study visits to monitor biochemical safety parameters for medical treatment. Between follow-up visits for this study, patients will follow guideline-based safety monitoring at the local psychiatric hospital.

During the PET neuroimaging, participants will have two catheters, one arterial and one venous. Vascular puncture can result in a light degree of pain. The risk of infection is negligible.

PET: Injection of the radiotracer may cause slight pain and redness, which should rapidly resolve. The radiotracers [15O]H2O and [11C]OHB are radiolabeled versions of their naturally occurring versions, thus sharing their chemical properties. They are given in non-pharmacological doses. [18F]FDG is an analogue of glucose, given in non-pharmacological dose (\<1 nanogram). Allergic reactions have been described, but are extremely rare - it has been used routinely in the workup of cancer patients through decades. Ultimately, no pharmacologic or immunologic side effects are to be expected from the radiotracers.

The amount of radiation to healthy controls will be 4.6 mSv. Since patients have two study days, the total radiation dose to patients will be 9.2 mSv. The mean background radiation in Denmark is approximately 3 mSv per year. Thus, healthy subjects and patients will get approximately 1½ and 3 times the yearly background radiation during the study. In Denmark, the lifetime risk of lethal cancer is approximately 25%. The radioactive dose of 9.2 mSv administered to patients in this study, may increase the risk by 0.05% (from 25% to 25.05%). The radioactive dose of 4.6 mSv administered to healthy controls in this study, may increase the risk by 0.02% (from 25% to 25.02%).

Study duration 2025-2027.

03

Conditions studied

  • Schizophrenia Disorder

Browse trials for

Keywords

  • Schizophrenia
  • PET neuroimaging
  • Brain energy substrate metabolism
  • Ketone bodies
  • Glucose
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Antipsychotic-naive patients with FES and healthy controls

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for patients with FES

  1. Age 18-35 years
  2. Diagnosed with FES (ICD-10: F20)
  3. Able to give informed oral and written consent.

Inclusion criteria for healthy controls

  1. Age 18-35 years
  2. No mental disorder (ICD-10: F00-99)
  3. Able to give informed oral and written consent.

Exclusion Criteria:

Exclusion criteria for patients with FES

  1. Any coercive measure including patients in forensic psychiatry
  2. In a clinical condition where the treating clinician evaluates that the patient is not able to attend the research study.
  3. Previous use of AP at an antipsychotic dose (except for Risperidone ≤0.5 mg, Abilify ≤2.5 mg, Seroquel ≤50 mg or Zyprexa ≤2.5 mg) for more than 2 continuous weeks in the past year and/or 6 weeks over a lifetime
  4. Use of an antipsychotic in the last 3 months before inclusion at a dose greater than:

    4.1 Seroquel/Quetiapine 50 mg 4.2 Risperdal/Risperidone 0.5 mg

  5. Comorbidity: Borderline intelligence or intellectual disability, autism spectrum disorder, decompensated substance use disorder, psychosis induced by a medical condition or psychosis induced by medication or drug use.
  6. Pregnancy, childbirth within the past 6 months, or breastfeeding. Female participants should use an effective .
  7. to MRI (metal, severe claustrophobia).
  8. Acute suicidal thoughts (e.g., resulting in hospitalization)
  9. Diabetes mellitus type 1. History of severe head trauma, stroke, chemotherapy or brain surgery. Hypo- or hyperthyroidism. Epilepsy. Systemic hormone treatment.
  10. Other conditions interfering with participation according to the qualified physician's judgment.

Exclusion criteria for healthy controls

  1. Previous use of an antipsychotic dose (except for Risperidone ≤0.5 mg, Abilify ≤2.5 mg, Seroquel ≤50 mg or Zyprexa ≤2.5 mg) for more than 2 continuous weeks in the past year and/or 6 weeks over a lifetime
  2. Use of AP in the last 3 months before inclusion at a dose greater than:

    1. Seroquel/Quetiapine 50 mg
    2. Risperdal/Risperidone 0.5 mg
  3. Pregnancy, childbirth within the past 6 months, or breastfeeding. Female participants should use an effective contraception.
  4. Contraindications to MRI (metal, severe claustrophobia).
  5. Diabetes mellitus type 1. History of severe head trauma, stroke, chemotherapy or brain surgery. Hypo- or hyperthyroidism. Epilepsy. Systemic glucocorticoid hormone treatment.
  6. Other conditions interfering with participation according to the qualified physician's judgment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
34 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with first-episode schizophrenia
  • Healthy controls
06

What researchers measure

Primary outcomes

  1. Whole brain ketone and glucose metabolism in FES compared to healthy controls measured via PET

    Time frame: At enrollment, i.e. at the baseline PET scan

  2. Whole brain ketone and glucose metabolism in FES after antipsychotic treatment

    Time frame: From baseline scan to the follow-up scan after 4-8 weeks of antipsychotic treatment

Secondary outcomes

  1. Correlation between antipsychotic response, as measured on the PANSS-6, with the change in brain ketone and glucose metabolism in patients with FES

    Time frame: From baseline to follow-up scan after 4-8 weeks of antipsychotic treatment

  2. Correlation between the MCCB with the change in brain ketone and glucose metabolism in patients with FES

    Time frame: From baseline to follow-up scan after 4-8 weeks of antipsychotic treatment

07

Study locations

1 of 1 sites recruiting
  • Aarhus University Hospital, Psychosis Research Unit
    Aarhus, Denmark
    Recruiting
    • Ole Köhler-Forsberg · Contactkarkoe@rm.dk · 004578471610
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's planned 32 months is below that.

Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 30, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309172
Lead sponsor
Ole Köhler-Forsberg
Responsible party
Ole Köhler-Forsberg (MD, PhD, Assoc. Professor, University of Aarhus) — Sponsor-investigator
First posted
Dec 30, 2025
Start date
Apr 15, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 30, 2025

Study contacts

Ole Köhler-Forsberg, MD, PhD, DMSc
Contact
karkoe@rm.dk
004578471610

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion